• The trial is a dose escalation study eval­u­ating safety and feasibility of T-cell Natural Killer Receptor NKG2D in patients with acute myeloid leukemia or mul­ti­ple myeloma
• No dose limiting toxicity re­ported of the last patient of the sec­ond dose level
• First patient of third dose level (10^7 cells) started cell processing

Mont-Saint-Guibert, Belgium (Press Release) – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and devel­op­ment of engi­neered cell ther­a­pies, with clin­i­cal pro­grams in cardio­vascular dis­ease and immuno-oncology, to­day an­nounced the com­ple­tion of the 21-day safety follow-up of the last patient en­rolled in the sec­ond dose level in the Phase I/IIa clin­i­cal trial eval­u­ating the safety and feasibility of its NKR-2 T-cell ther­apy using T-cells with NKG2D re­cep­tor in cancer patients suffer­ing from acute myeloid leukemia …

• No dose limiting toxicity re­lated to the inves­ti­ga­tional treat­ment re­ported at 30 days post treat­ment of the first patient of the sec­ond dose-level
• The trial is a dose escalation study eval­u­ating safety and feasibility of a CAR T-cell ther­apy in patients with acute myeloid leukemia or mul­ti­ple myeloma.

Mont-Saint-Guibert, Belgium (Press Release) Celyad (Paris:​CYAD) (Brussels:​CYAD) (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and devel­op­ment of engi­neered cell ther­a­pies, with clin­i­cal pro­grams in cardiovascular dis­ease and immuno-oncology, to­day an­nounced the com­ple­tion of the 30-day safety follow-up of the first patient en­rolled in the sec­ond cohort in the Phase I clin­i­cal trial eval­u­ating the safety and feasibility of its NKG2D CAR T-cell ther­apy, in cancer patients suffer­ing from acute myeloid leukemia (AML) or mul­ti­ple myeloma (MM).

Dr. …